AMRI, 26 Corporate Circle, Albany, NY 12212, USA.
Bioorg Med Chem Lett. 2010 May 1;20(9):2912-5. doi: 10.1016/j.bmcl.2010.03.028. Epub 2010 Mar 12.
SAR around non-peptidic potent bombesin receptor subtype-3 (BRS-3) agonist lead 2 is presented. Attempts to replace the carboxylic acid with heterocyclic isosteres to improve oral bioavailability and brain penetration are described.
呈现了非肽类强效蛙皮素受体亚型 3(BRS-3)激动剂先导 2 的 SAR 研究结果。描述了尝试用杂环等排体替代羧酸以提高口服生物利用度和脑穿透性的努力。